AÑOS DE PUBLICACIÓN:
2019 || 2018 || 2017 || 2016 || 2015 || 2014 || 2013 || 2012 || 2011 || 2010 || 2009 || 2008 || 2007 |
2018
Interethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and predicted drug metabolism phenotypes among 6060 ibero- and native americans: RIBEF-CEIBA Consortium report on population pharmacogenomics.
Naranjo MG, Rodrigues-Soares F, Peñas-Lledó EM, Tarazona-Santos E, Fariñas H, Rodeiro I, Terán E, Grazina M, Moya GE, López-López M, Sarmiento AP, Calzadilla LR, Ramírez-Roa R, Ortiz-López R, Estévez-Carrizo FE, Sosa-Macías M, Barrantes R, LLerena A; CEIBA-Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics RIBEF.
OMICS. 2018 Sep;22(9):575-588.
Carbamazepine adverse drug reactions.
Fricke-Galindo I, LLerena A, Jung-Cook H, López-López M.E
Expert Rev Clin Pharmacol. 2018 Jul;11(7):705-718.
Genetic structure of pharmacogenetic biomarkers in Brazil inferred from a systematic review and population-based cohorts: a RIBEF/EPIGEN-Brazil initiative.
Rodrigues-Soares F, Kehdy FSG, Sampaio-Coelho J, Andrade PXC, Céspedes-Garro C, Zolini C, Aquino MM, Barreto ML, Horta BL, Lima-Costa MF, Pereira AC, LLerena A, Tarazona-Santos E.
Pharmacogenomics J. 2018 Dec;18(6):749-759.